# A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

> **NCT07142811** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vir Biotechnology, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Viral Hepatitis

## Interventions

- **DRUG:** Tobevibart
- **DRUG:** Elebsiran
- **DRUG:** Bulevirtide

## Key facts

- **NCT ID:** NCT07142811
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-05
- **Primary completion:** 2026-11
- **Final completion:** 2030-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07142811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07142811, "A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07142811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*